ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Lactate Metabolism-Immune Regulation-Related Gene Signature in Lower-Grade Gliomas: Prognostic Model Development and Immune Characterization.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Low-grade gliomas represent a diverse category of central nervous system tumors, characterized by considerable variability in prognosis. Metabolic reprogramming, particularly lactate metabolism, has been associated with the tumor immune microenvironment; however, the prognostic significance of the related genes in LGG is still not well understood. This study used TCGA and CGGA cohorts to perform consensus clustering based on genes involved in lactate metabolism. A predictive model was constructed using differential analysis, Cox regression, and LASSO methods. The model's association with immune cell infiltration, TMB, and drug responsiveness was also evaluated. The function of the key gene PLA2G2A was validated using RT-qPCR, Western blot, immunofluorescence, ELISA, CCK-8, Transwell assays, and mouse tumorigenesis experiments. Consensus clustering classified LGG into two distinct subtypes, each showing significant variations in survival and immune profiles. The three-gene signature (VAV3, TNFRSF12A, PLA2G2A) effectively distinguished high-risk from low-risk patients, demonstrating high predictive accuracy in both TCGA and CGGA datasets. Patients categorized as high-risk showed reduced immune infiltration, increased TMB, and a worse prognosis. Additionally, they showed increased sensitivity to tyrosine kinase inhibitors and platinum-based therapies. Functional experiments showed that PLA2G2A was highly expressed in gliomas, and its downregulation notably reduced tumor cell proliferation, migration, invasion, and growth in vivo, while reversing the epithelial-mesenchymal transition. This study proposes and validates a novel three-gene prognostic model that reflects the metabolic-immune interactions in LGG, predicts patient prognosis, and suggests potential therapeutic targets. The functional validation of PLA2G2A further underscores its potential as a therapeutic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.